Company: RNAC
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001453687-25-000075
Chunk: 58

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 58
---
 our Named Executive Officers:

| Named Executive Officer        |     | Target Annual Cash Bonus Opportunity |     | Amount Related to Corporate Performance Objectives |     | Actual Annual Cash Bonus Payment |     | Percentage of Target Annual Cash Bonus Opportunity |
| Carsten Brunn, Ph.D.           |     |                             $353,500 |     |                                           $353,500 |     |                         $459,545 |     | 130%                                               |
| Blaine Davis                   |     |                             $184,800 |     |                                           $184,800 |     |                         $240,240 |     | 130%                                               |
| Metin Kurtoglu, M.D., Ph.D.(1) |     |                             $176,000 |     |                                           $176,000 |     |                         $228,800 |     | 130%                                               |
| Christopher Jewell, Ph.D.(2)   |     |                             $168,000 |     |                                           $168,000 |     |                         $218,400 |     | 130%                                               |

<div align='center'>34</div>

(1) Dr. Kurtoglu was appointed to serve as the Company’s Chief Operating Officer on November 13, 2023. On March 28, 2024, Dr. Kurtoglu’s title was changed to Chief Technology Officer.

(2) Dr. Jewell was appointed to serve as the Company’s Chief Scientific Officer on November 13, 2023.

#### Long-Term Incentive Compensation
We use long-term incentive compensation in the form of equity awards to motivate our executive officers, including our Named Executive Officers, by providing them with the opportunity to build an equity interest in the Company and to share in the potential appreciation of the value of our Common Stock. Historically, we have relied on options to purchase shares of our Common Stock and, beginning in 2018, RSU awards that may be settled for shares of our Common Stock as the principal vehicles for delivering long-term incentive compensation opportunities to our executive officers. The Compensation Committee views equity awards, whether the awards are subject to time-based vesting requirements or are to be earned based on the attainment of specific performance objectives, as inherently variable since the grant date fair value of these awards may not necessarily be indicative of their value when, and if, the shares of our Common Stock underlying these awards are ever earned or purchased. Additionally, the Compensation Committee believes these awards reward the individual performance of participants, in contrast to stock options, which only